CAR T-cell Therapy Market Size, Share & Trends Analysis Report by Product (Abecma, Breyanzi), By Disease Indication (Lymphoma, Leukemia, Multiple Myeloma), By End-use, By Region, And Segment Forecasts, 2023

The global CAR T-cell therapy market size is expected to reach USD 15.97 billion by 2030, expanding at 23.32% CAGR from 2023 to 2030, according to a new report by Grand View Research, Inc. CAR T-cell therapy presents a paradigm shift in the treatment of blood cancers such as lymphoma, multiple myeloma, and leukemia by utilizing the patient's immune system to terminate cancer cells. The rising prevalence of cancer types such as multiple myeloma in developing countries is driving the market. Rampant regulatory support in the form of product approvals and an intensive product pipeline of drugs further strengthens the industry. For instance, as per the U.S. National Library of Medicine April 2023, around 310 studies pertinent to CAR T-cells are being conducted across early phase I, phase I, and phase II in various parts of the world.

Various players are entering into strategic partnerships along with geographic expansion to necessitate therapy coverage across the world. Thereby, companies are adopting strategies to increase the geographical footprint in countries without access to potential cures or treatments for blood cancers. For instance, on August 31, 2022, Kite, a medical company operating under Gilead announced the expansion of CAR T-cell therapy in regions of Saudi Arabia, Brazil, and Singapore. The company reported an occurrence of 1000 or higher cases of non-Hodgkin lymphoma (NHL) in Singapore, while around 1700 cases of the disease are diagnosed in Saudi Arabia. Similarly, in Brazil, around 12000 cases of NHL are found each year.

The COVID-19 pandemic has made it difficult to administer CAR T-cell therapy to patients, particularly in the early stages of the pandemic when many hospitals and clinics were overwhelmed with COVID-19 patients. Many hospitals had to postpone or cancel elective procedures, including CAR T-cell therapy, to free up resources for COVID-19 patients. In addition, CAR T-cell therapy has significant side effects, including cytokine release syndrome (CRS), which can cause fever, low blood pressure, and organ damage which mimics the symptoms of COVID-19, thereby, curating problems to treat for condition.

Moreover, hospitals and cancer care centers emerging in developing countries are progressing with the adoption of CAR T-cells. These centers thrive as cost and time-efficient cancer treatments allow the market to grow holistically. For instance, in August 2022, Immunotherapy Institute, a cancer treatment center in Mexico began operations to offer CAR T-cells for American and Canadian patients. Similarly, in Israel, the therapy can be expedited in about 10 days owing to the entire process being conducted in-house, with notable cost reductions.

The lack of skilled professionals in emerging nations coupled with the high cost associated with the therapy remain challenges to market growth. However, rising awareness and increasing approvals for technologically advanced CAR T-cell therapy are anticipated to mitigate these challenges and contribute to market growth over the forecast period. According to Cancer Treatment Centers of America, six CAR T-cell therapies were approved by U.S. FDA for the treatment of blood cancers as of 2023.

CAR T-cell Therapy Market Report Highlights

By product, the Yescarta (axicabtagene ciloleucel) segment dominated the market with a share of 43.76% in 2022. The high usage of Yescarta can be attributed to strong performance and improved survivability in adults suffering from relapsed B-cell large lymphoma
Lymphoma accounted for the largest share of 57.15% in the disease indication segment in 2022. The high penetration of the market segment owes itself to the significant prevalence of the condition across the world. Additionally, the strong product focus by market players to eliminate the CD-19 antigen drives growth
By end-use, the hospital segment captured a majority share of 56.26% in 2022 due to the robust presence of fiscal and operational resources. Additionally, in-house labs for hospitals expedite the process faster, helping to gain a strong share
North America has shown a dominant position in the market with a 66.70% share in 2022. The primary reason for a sizable share can be attributed to the patient volume and overall access to general and complex healthcare, with speedy approvals and robust medical insurance coverage

Product Code: GVR-4-68040-090-4

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope
- 1.1.1. Market definitions
  - 1.1.1.1. Product segment
  - 1.1.1.2. Disease indication segment
  - 1.1.1.3. End-use segment
1.2. Information Procurement
- 1.2.1. Market formulation & data visualization
- 1.2.2. Data validation & publishing
1.3. Research Assumptions
1.4. Research Methodology
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
1.5. Information or Data Analysis
- 1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
- 1.7.1. Commodity flow analysis
  - 1.7.1.1. Approach 1: Commodity flow approach
1.8. List of Secondary Sources
1.9. Global Market: CAGR CalculationObjectives

Chapter 2. Executive Summary

2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
3.2. Market Trends and Outlook
3.3. Market Dynamics
- 3.3.1. Market Driver Analysis
  - 3.3.1.1. Growing cases of Cancer Malignancies across population
  - 3.3.1.2. Targeted treatment approach mitigates relapsed or refracted blood cancer cases.
  - 3.3.1.3. Robust product pipeline with regulatory approvals across geographies.
- 3.3.2. Market Restraint Analysis
  - 3.3.2.1. High drug cost impedes the market growth
  - 3.3.2.2. Side-effects of CAR T-cell therapy
  - 3.3.2.3. Complex Manufacturing and Supply Chain
3.4. Business Environment Analysis
- 3.4.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
- 3.4.2. Porter's Five Forces Analysis
- 3.4.3. COVID-19 Impact Analysis

Chapter 4. CAR T-cell Therapy Market: Product Estimates & Trend Analysis

4.1. Product Movement Analysis & Market Share, 2022 & 2030
4.2. CAR T-cell Therapy Market Estimates & Forecast, By Product (USD Million)
4.3. Abecma (idecabtagene vicleucel)
- 4.3.1. Global Abecma (idecabtagene vicleucel) Market, 2018 - 2030 (USD Million)
4.4. Breyanzi (lisocabtagene maraleucel)
- 4.4.1. Global Breyanzi (lisocabtagene maraleucel) Market, 2018 - 2030 (USD Million)
4.5. Carvykti (ciltacabtagene autoleucel)
- 4.5.1. Global Carvykti (ciltacabtagene autoleucel) Market, 2018 - 2030 (USD Million)
4.6. Kymriah (tisagenlecleucel)
- 4.6.1. Global Kymriah (tisagenlecleucel) Market, 2018 - 2030 (USD Million)
4.7. Tecartus (brexucabtagene autoleucel)
- 4.7.1. Global Tecartus (brexucabtagene autoleucel) Market, 2018 - 2030 (USD Million)
4.8. Yescarta (axicabtagene ciloleucel)
- 4.8.1. Global Yescarta (axicabtagene ciloleucel) Market, 2018 - 2030 (USD Million)
4.9. Others
- 4.9.1. Global Others Market, 2018 - 2030 (USD Million)

Chapter 5. CAR T-cell Therapy Market: Disease Indication Estimates & Trend Analysis

5.1. Disease Indication Movement Analysis & Market Share, 2022& 2030
5.2. CAR T-cell Therapy Market Estimates & Forecast, By Disease Indication (USD Million)
5.3. Leukemia
- 5.3.1. Global Leukemia Market, 2018 - 2030 (USD Million)
5.4. Lymphoma
- 5.4.1. Global Lymphoma Market, 2018 - 2030 (USD Million)
5.5. Multiple Myeloma
- 5.5.1. Global Multiple Myeloma Market, 2018 - 2030 (USD Million)

Chapter 6. End-use Business Analysis

6.1. End-use Movement Analysis & Market Share, 2022& 2030
6.2. CAR T-cell Therapy Market Estimates & Forecast, By End-use (USD Million)
6.3. Hospitals
- 6.3.1. Hospitals Market, 2018 - 2030 (USD Million)
6.4. Cancer Treatment Centers
- 6.4.1. Cancer Treatment Market, 2018 - 2030 (USD Million)

Chapter 7. Regional Business Analysis

7.1. CAR T-cell Therapy Market: Region Outlook
7.2. North America
- 7.2.1. North America CAR T-cell Therapy market estimates and forecast, 2018 - 2030 (USD Million)
- 7.2.2. The U.S.
  - 7.2.2.1. Key Country Dynamics
  - 7.2.2.2. Competitive Scenario
  - 7.2.2.3. Regulatory Framework
  - 7.2.2.4. Disease Prevalence
  - 7.2.2.5. U.S. CAR T-cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
- 7.2.3. Canada
  - 7.2.3.1. Key Country Dynamics
  - 7.2.3.2. Competitive Scenario
  - 7.2.3.3. Regulatory Framework
  - 7.2.3.4. Disease Prevalence
  - 7.2.3.5. Canada CAR T-cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
7.3. Europe
- 7.3.1. Europe CAR T-cell Therapy market estimates and forecast, 2018 - 2030 (USD Million)
- 7.3.2. Germany
  - 7.3.2.1. Key Country Dynamics
  - 7.3.2.2. Competitive Scenario
  - 7.3.2.3. Regulatory Framework
  - 7.3.2.4. Disease Prevalence
  - 7.3.2.5. Germany CAR T-cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
- 7.3.3. UK
  - 7.3.3.1. Key Country Dynamics
  - 7.3.3.2. Competitive Scenario
  - 7.3.3.3. Regulatory Framework
  - 7.3.3.4. Disease Prevalence
  - 7.3.3.5. UK CAR T-cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
7.4. Asia Pacific
- 7.4.1. Asia Pacific CAR T-cell Therapy market estimates and forecast, 2018 - 2030 (USD Million)
- 7.4.2. Japan
  - 7.4.2.1. Key Country Dynamics
  - 7.4.2.2. Competitive Scenario
  - 7.4.2.3. Regulatory Framework
  - 7.4.2.4. Disease Prevalence
  - 7.4.2.5. Japan CAR T-cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
- 7.4.3. China
  - 7.4.3.1. Key Country Dynamics
  - 7.4.3.2. Competitive Scenario
  - 7.4.3.3. Regulatory Framework
  - 7.4.3.4. Disease Prevalence
  - 7.4.3.5. China CAR T-cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
7.5. Rest of World
- 7.5.1. Rest of World CAR T-cell Therapy market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

8.1. Company Categorization
8.2. Strategy Mapping
8.3. Company Profiles/Listing
- 8.3.1. Bristol-Myers Squibb Company
  - 8.3.1.1. Overview
  - 8.3.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
  - 8.3.1.3. Product Benchmarking
  - 8.3.1.4. Strategic Initiatives
- 8.3.2. Novartis AG
  - 8.3.2.1. Overview
  - 8.3.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
  - 8.3.2.3. Product Benchmarking
  - 8.3.2.4. Strategic Initiatives
  - 8.3.2.5. Overview
  - 8.3.2.6. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
  - 8.3.2.7. Product Benchmarking
  - 8.3.2.8. Strategic Initiatives
- 8.3.3. Gilead Sciences Inc
  - 8.3.3.1. Overview
  - 8.3.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
  - 8.3.3.3. Product Benchmarking
  - 8.3.3.4. Strategic Initiatives
- 8.3.4. Bluebird Bio Inc
  - 8.3.4.1. Overview
  - 8.3.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
  - 8.3.4.3. Product Benchmarking
  - 8.3.4.4. Strategic Initiatives
- 8.3.5. Johnson & Johnson Services Inc
  - 8.3.5.1. Overview
  - 8.3.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
  - 8.3.5.3. Product Benchmarking
  - 8.3.5.4. Strategic Initiatives
- 8.3.6. Merck & Co.
  - 8.3.6.1. Overview
  - 8.3.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
  - 8.3.6.3. Product Benchmarking
  - 8.3.6.4. Strategic Initiatives
- 8.3.7. Sorrento Therapeutics Inc
  - 8.3.7.1. Overview
  - 8.3.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
  - 8.3.7.3. Product Benchmarking
  - 8.3.7.4. Strategic Initiatives
- 8.3.8. Sangamo Therapeutics
  - 8.3.8.1. Overview
  - 8.3.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
  - 8.3.8.3. Product Benchmarking
  - 8.3.8.4. Strategic Initiatives
- 8.3.9. GSK Plc.
  - 8.3.9.1. Overview
  - 8.3.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
  - 8.3.9.3. Product Benchmarking
  - 8.3.9.4. Strategic Initiatives
- 8.3.10. JW Therapeutics (Shanghai) Co., Ltd.
  - 8.3.10.1. Overview
  - 8.3.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
  - 8.3.10.3. Product Benchmarking
  - 8.3.10.4. Strategic Initiatives

Product Code: GVR-4-68040-090-4

List of Tables

Table 1 List of Abbreviations
Table 2 Global CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
Table 3 Global CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
Table 4 Global CAR T-cell therapy market, by end-use, 2018 - 2030 (USD Million)
Table 5 Global CAR T-cell therapy market, by region, 2018 - 2030 (USD Million)
Table 6 North America CAR T-cell therapy market, by country, 2018 - 2030 (USD Million)
Table 7 North America CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
Table 8 North America CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
Table 9 North America CAR T-cell therapy market, by end-use, 2018 - 2030 (USD Million)
Table 10 U.S. CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
Table 11 U.S. CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
Table 12 U.S. CAR T-cell therapy market, by end-use, 2018 - 2030 (USD Million)
Table 13 Canada CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
Table 14 Canada CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
Table 15 Canada CAR T-cell therapy market, by end-use, 2018 - 2030 (USD Million)
Table 16 Europe CAR T-cell therapy market, by country, 2018 - 2030 (USD Million)
Table 17 Europe CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
Table 18 Europe CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
Table 19 Europe CAR T-cell therapy market, by end-use, 2018 - 2030 (USD Million)
Table 20 Germany CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
Table 21 Germany CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
Table 22 Germany CAR T-cell therapy market, by end-use, 2018 - 2030 (USD Million)
Table 23 UK CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
Table 24 UK CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
Table 25 UK CAR T-cell therapy market, by end-use, 2018 - 2030 (USD Million)
Table 26 UK CAR T-cell therapy market, by end-use, 2018 - 2030 (USD Million)
Table 27 Rest of Europe CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
Table 28 Rest of Europe CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
Table 29 Rest of Europe CAR T-cell therapy market, by end-use, 2018 - 2030 (USD Million)
Table 30 Asia Pacific CAR T-cell therapy market, by country, 2018 - 2030 (USD Million)
Table 31 Asia Pacific CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
Table 32 Asia Pacific CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
Table 33 Asia Pacific CAR T-cell therapy market, by end-use, 2018 - 2030 (USD Million)
Table 34 China CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
Table 35 China CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
Table 36 China CAR T-cell therapy market, by end-use, 2018 - 2030 (USD Million)
Table 37 Japan CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
Table 38 Japan CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
Table 39 Japan CAR T-cell therapy market, by end-use, 2018 - 2030 (USD Million)
Table 40 Rest of Asia-Pacific CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
Table 41 Rest of Asia-Pacific CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
Table 42 Rest of Asia-Pacific CAR T-cell therapy market, by end-use, 2018 - 2030 (USD Million)
Table 43 Rest of World CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
Table 44 Rest of World CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
Table 45 Rest of World CAR T-cell therapy market, by end-use, 2018 - 2030 (USD Million)

List of Figures

Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value chain-based sizing & forecasting
Fig. 6 Market formulation & validation
Fig. 7 CAR T-cell Therapy sequencing market segmentation
Fig. 8 Market snapshot, 2022
Fig. 9 Market trends & outlook
Fig. 10 Market driver relevance analysis (current & future impact)
Fig. 11 Market restraint relevance analysis (current & future impact)
Fig. 12 Swot analysis, by factor (political & legal, economic and technological)
Fig. 13 Porter's five forces analysis
Fig. 14 Market penetration & growth prospect mapping, 2022
Fig. 15 Global CAR T-cell therapy: product movement analysis
Fig. 16 Global CAR T-cell therapy, for Abecma, 2018 - 2030 (USD million)
Fig. 17 Global CAR T-cell therapy, for Breyanzi, 2018 - 2030 (USD million)
Fig. 18 Global CAR T-cell therapy, for Carvykti, 2018 - 2030 (USD million)
Fig. 19 Global CAR T-cell therapy, for Kymriah, 2018 - 2030 (USD million)
Fig. 20 Global CAR T-cell therapy, for Tecartus, 2018 - 2030 (USD million)
Fig. 21 Global CAR T-cell therapy, for Yescarta, 2018 - 2030 (USD million)
Fig. 22 Global CAR T-cell therapy: disease indication movement analysis
Fig. 23 Global CAR T-cell therapy, for leukaemia, 2018 - 2030 (USD million)
Fig. 24 Global CAR T-cell therapy, for lymphoma, 2018 - 2030 (USD million)
Fig. 25 Global CAR T-cell therapy, for multiple myeloma, 2018 - 2030 (USD million)
Fig. 26 Global CAR T-cell therapy: end-use movement analysis
Fig. 27 Global CAR T-cell therapy, for hospitals, 2018 - 2030 (USD million)
Fig. 28 Global CAR T-cell therapy, for cancer treatment centers, 2018 - 2030 (USD million)
Fig. 29 Regional marketplace: key takeaways
Fig. 30 Regional outlook, 2022 & 2030
Fig. 31 Global CAR T-cell therapy: region movement analysis
Fig. 32 North America CAR T-cell therapy, 2018 - 2030 (USD million)
Fig. 33 U.S. CAR T-cell therapy, 2018 - 2030 (USD million)
Fig. 34 Canada CAR T-cell therapy, 2018 - 2030 (USD million)
Fig. 35 Europe CAR T-cell therapy, 2018 - 2030 (USD million)
Fig. 36 Germany CAR T-cell therapy, 2018 - 2030 (USD million)
Fig. 37 UK CAR T-cell therapy, 2018 - 2030 (USD million)
Fig. 38 Rest of Europe CAR T-cell therapy, 2018 - 2030 (USD million)
Fig. 39 Asia Pacific CAR T-cell therapy, 2018 - 2030 (USD million)
Fig. 40 Japan CAR T-cell therapy, 2018 - 2030 (USD million)
Fig. 41 China CAR T-cell therapy, 2018 - 2030 (USD million)
Fig. 42 Rest of Asia Pacific CAR T-cell therapy, 2018 - 2030 (USD million)
Fig. 43 Rest of World CAR T-cell therapy, 2018 - 2030 (USD million)

CAR T-cell Therapy Market Size, Share & Trends Analysis Report by Product (Abecma, Breyanzi), By Disease Indication (Lymphoma, Leukemia, Multiple Myeloma), By End-use, By Region, And Segment Forecasts, 2023 - 2030

Description

Table of Contents

List of Tables

CAR T-cell Therapy Market Growth & Trends

CAR T-cell Therapy Market Report Highlights

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Market Variables, Trends, & Scope

Chapter 4. CAR T-cell Therapy Market: Product Estimates & Trend Analysis

Chapter 5. CAR T-cell Therapy Market: Disease Indication Estimates & Trend Analysis

Chapter 6. End-use Business Analysis

Chapter 7. Regional Business Analysis

Chapter 8. Competitive Landscape

List of Tables

List of Figures